First trading day on Nasdaq First North for NextCell
NextCell Pharma AB (“NextCell” or “The Company”) announced that as of today, the company’s share is being traded on Nasdaq First North Growth Market. The traditional bell ringing is skipped due to the prevailing COVID-19 pandemic.
"The list change is a natural step in our development and is expected to attract a broader group of investors, as well as give the company better access to the Swedish and international capital markets. Our international network is increasing and joining Nasdaq can further facilitate NextCell’s visibility," says Mathias Svahn, CEO.
The shares in NextCell will be traded with unchanged ticker (NXTCL) and ISIN code (SE0009723125) and shareholders in NextCell need not take any action in connection with the list change.
FNCA Sweden AB is NextCells Certified Adviser on Nasdaq First North Stockholm, phone 08-528 00 399, e-mail info@fnca.se.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
Website:
www.cellaviva.se
www.cellaviva.dk
About NextCell Pharma AB:
NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.
Taggar: